Compass Therapeutics (CMPX) EBIAT: 2023-2025
Historic EBIAT for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$14.3 million.
- Compass Therapeutics' EBIAT fell 36.05% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$65.8 million, marking a year-over-year decrease of 37.79%. This contributed to the annual value of -$49.4 million for FY2024, which is 16.19% down from last year.
- Latest data reveals that Compass Therapeutics reported EBIAT of -$14.3 million as of Q3 2025, which was up 28.28% from -$19.9 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' EBIAT registered a high of -$7.8 million during Q1 2023, and its lowest value of -$19.9 million during Q2 2025.
- Moreover, its 3-year median value for EBIAT was -$13.1 million (2024), whereas its average is -$13.0 million.
- Data for Compass Therapeutics' EBIAT shows a maximum YoY tumbled of 54.19% (in 2025) over the last 5 years.
- Over the past 3 years, Compass Therapeutics' EBIAT (Quarterly) stood at -$13.4 million in 2023, then fell by 12.06% to -$15.0 million in 2024, then plummeted by 36.05% to -$14.3 million in 2025.
- Its EBIAT was -$14.3 million in Q3 2025, compared to -$19.9 million in Q2 2025 and -$16.6 million in Q1 2025.